Dermatologic drug reactions

Immunology and Allergy Clinics of North America

Volumn 24, Issue 3, 2004, Pages 399-423

  McKenna, Jeffrey K ^a   Leiferman, Kristin M ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ANTACID AGENT; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; ANTIPYRETIC AGENT; ATROPINE; BENZODIAZEPINE; CHLORAL HYDRATE; CROMOGLYCATE DISODIUM; DIGITALIS; DIPHENHYDRAMINE; FERROUS SULFATE; GLUCOCORTICOID; INSULIN; ISOSORBIDE DINITRATE; LAXATIVE; LOCAL ANESTHETIC AGENT; MUSCLE RELAXANT AGENT; NITRATE; NYSTATIN; ORAL CONTRACEPTIVE AGENT; PARACETAMOL; PREDNISONE; PROMETHAZINE; PROPRANOLOL DERIVATIVE; SPIRONOLACTONE; THEOPHYLLINE; THYROID HORMONE; UNINDEXED DRUG; VITAMIN B COMPLEX;

ACNE; ALLERGIC VASCULITIS; ALOPECIA; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ARTHUS PHENOMENON; BACTERIAL INFECTION; BLISTER; BULLOUS SKIN DISEASE; CONTACT DERMATITIS; CYTOTOXICITY; DELAYED HYPERSENSITIVITY; DERMATITIS HERPETIFORMIS; DIARRHEA; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; EDEMA; EPSTEIN BARR VIRUS; ERYTHEMA MULTIFORME; ERYTHEMA NODOSUM; FEVER; HEMOLYTIC ANEMIA; HEPATITIS B; HERPES VIRUS; HERPES VIRUS INFECTION; HUMAN; HYPERSENSITIVITY REACTION; INFECTIOUS MONONUCLEOSIS; INSECT BITE; LICHENOID; MUCOSA INFLAMMATION; MYCOPLASMA; NAUSEA; PAIN; PEMPHIGOID; PEMPHIGUS; PENIS GLANS; PHOTOALLERGY; PORPHYRIA CUTANEA TARDA; PRIORITY JOURNAL; PRURITUS; PSORIASIS; RASH; REVIEW; SERUM SICKNESS; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME; STOMATITIS; STRIDOR; THROMBOCYTOPENIA; TOXIC EPIDERMAL NECROLYSIS; URTICARIA; VIRUS INFECTION; VOMITING;

DIAGNOSIS, DIFFERENTIAL; DRUG ERUPTIONS; HUMANS; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 3042704282     PISSN: 08898561     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.iac.2004.03.007     Document Type: Review

References (70)

1. Bigby M. Rates of cutaneous reactions to drugs. Arch Dermatol. 137(6):2001;765-770
2. Jerome Z., Litt M. Drug eruption reference manual. 8th edition:2002;Parthenon Publishing Group, New York
3. Roujeau J.C., Stern R.S. Severe adverse cutaneous reactions to drugs. N Engl J Med. 331(19):1994;1272-1285
4. Pichler W.J. Delayed drug hypersensitivity reactions. Ann Intern Med. 139(8):2003;683-693
5. Samolitis N., Leiferman K.M., Gleich G.J. The IgE-mediated cutaneous late-phase reaction. Greaves M., Kaplan A. Urticaria and angioedema. 2004;119-140 Marcel Drekker, New York
6. Roujeau J.C. Treatment of severe drug eruptions. J Dermatol. 26(11):1999;718-722
7. Arndt K.A., Jick H. Rates of cutaneous reactions to drugs: a report from the Boston Collaborative Drug Surveillance Program. JAMA. 235(9):1976;918-923
8. van der Ven A.J., Koopmans P.P., Vree T.B., van der Meer J.W. Drug intolerance in HIV disease. J Antimicrob Chemother. 34(1):1994;1-5
9. Kano Y., Shiohara T. Current understanding of cytomegalovirus infection in immunocompetent individuals. J Dermatol Sci. 22(3):2000;196-204
10. Fung M.A. The clinical and histopathologic spectrum of "dermal hypersensitivity reactions, " a nonspecific histologic diagnosis that is not very useful in clinical practice, and the concept of a "dermal hypersensitivity reaction pattern" J Am Acad Dermatol. 47(6):2002;898-907
11. Shin H.T., Chang M.W. Drug eruptions in children. Curr Probl Pediatr. 31(7):2001;207-234
12. Kaur S., Sarkar R., Thami G.P., Kanwar A.J. Anticonvulsant hypersensitivity syndrome. Pediatr Dermatol. 19(2):2002;142-145
13. Korkij W., Soltani K. Fixed drug eruption: a brief review. Arch Dermatol. 120(4):1984;520-524
14. Lisi P., Stingeni L. Fixed drug eruption: bullous form. Clin Dermatol. 11(4):1993;461-466
15. Ozkaya-Bayazit E. Specific site involvement in fixed drug eruption. J Am Acad Dermatol. 49(6):2003;1003-1007
16. Mahboob A., Haroon T.S. Drugs causing fixed eruptions: a study of 450 cases. Int J Dermatol. 37(11):1998;833-838
17. Sharma V.K., Dhar S., Gill A.N. Drug related involvement of specific sites in fixed eruptions: a statistical evaluation. J Dermatol. 23(8):1996;530-534
18. Lin T.K., Hsu M.M., Lee J.Y. Clinical resemblance of widespread bullous fixed drug eruption to Stevens-Johnson syndrome or toxic epidermal necrolysis: report of two cases. J Formos Med Assoc. 101(8):2002;572-576
19. Pellicano R., Silvestris A., Iannantuono M., Ciavarella G., Lomuto M. Familial occurrence of fixed drug eruptions. Acta Derm Venereol. 72(4):1992;292-293
20. Pellicano R., Ciavarella G., Lomuto M., Di Giorgio G. Genetic susceptibility to fixed drug eruption: evidence for a link with HLA-B22. J Am Acad Dermatol. 30(1):1994;52-54
21. Greaves M.W. Chronic idiopathic urticaria. Curr Opin Allergy Clin Immunol. 3(5):2003;363-368
22. Sabroe R.A., Seed P.T., Francis D.M., Barr R.M., Black A.K., Greaves M.W. Chronic idiopathic urticaria: comparison of the clinical features of patients with and without anti-FcepsilonRI or anti-IgE autoantibodies. J Am Acad Dermatol. 40(3):1999;443-450
23. Nigen S., Knowles S.R., Shear N.H. Drug eruptions: approaching the diagnosis of drug-induced skin diseases. J Drugs Dermatol. 2(3):2003;278-299
24. Cousin F., Catelain A., Philips K., Favier B., Queuille E., Nicolas J.F. [Immediate hypersensitivity is rarely implicated in drug induced urticaria]. Ann Dermatol Venereol. 130(3):2003;321-324
25. Bircher A.J. Drug-induced urticaria and angioedema caused by non-IgE mediated pathomechanisms. Eur J Dermatol. 9(8):1999;657-663. quiz, 663
26. Steckelings U.M., Artuc M., Wollschlager T., Wiehstutz S., Henz B.M. Angiotensin-converting enzyme inhibitors as inducers of adverse cutaneous reactions. Acta Derm Venereol. 81(5):2001;321-325
27. Abdi R., Dong V.M., Lee C.J., Ntoso K.A. Angiotensin II receptor blocker-associated angioedema: on the heels of ACE inhibitor angioedema. Pharmacotherapy. 22(9):2002;1173-1175
28. Park B.K., Kitteringham N.R., Powell H., Pirmohamed M. Advances in molecular toxicology - towards understanding idiosyncratic drug toxicity. Toxicology. 153(1-3):2000;39-60
29. Zuberbier T., Greaves M.W., Juhlin L., Merk H., Stingl G., Henz B.M. Management of urticaria: a consensus report. J Invest Dermatol Symp Proc. 6:2001;128-131
30. Beylot C., Doutre M.S., Beylot-Barry M. Acute generalized exanthematous pustulosis. Semin Cutan Med Surg. 15(4):1996;244-249
31. Scheinfeld N., Wesson K., Perry P., Weinberg J. Acute generalized exanthematous pustulosis resembling toxic epidermal necrolysis caused by famotidine. Acta Derm Venereol. 83(1):2003;76-77
32. Saissi E.H., Beau-Salinas F., Jonville-Bera A.P., Lorette G., Autret-Leca E. [Drugs associated with acute generalized exanthematic pustulosis]. Ann Dermatol Venereol. 130(6-7):2003;612-618
33. Lee S., Artemi P., Holt D. Acute generalized exanthematous pustulosis. Australas J Dermatol. 36(1):1995;25-27
34. Mengesha Y.M., Bennett M.L. Pustular skin disorders: diagnosis and treatment. Am J Clin Dermatol. 3(6):2002;389-400
35. Roujeau J.C., Bioulac-Sage P., Bourseau C., et al. Acute generalized exanthematous pustulosis: analysis of 63 cases. Arch Dermatol. 127(9):1991;1333-1338
36. Mashiah J., Brenner S. A systemic reaction to patch testing for the evaluation of acute generalized exanthematous pustulosis. Arch Dermatol. 139(9):2003;1181-1183
37. Doyle M.K., Cuellar M.L. Drug-induced vasculitis. Expert Opin Drug Saf. 2(4):2003;401-409
38. Gungor E., Cirit A., Alli N., Karakayali G., Gur G., Artuz F. Prevalence of hepatitis C virus antibodies and cryoglobulinemia in patients with leukocytoclastic vasculitis. Dermatology. 198(1):1999;26-28
39. Buezo G.F., Garcia-Buey M., Rios-Buceta L., Borque M.J., Aragues M., Dauden E. Cryoglobulinemia and cutaneous leukocytoclastic vasculitis with hepatitis C virus infection. Int J Dermatol. 35(2):1996;112-115
40. Gibson L.E., Su W.P. Cutaneous vasculitis. Rheum Dis Clin North Am. 21(4):1995;1097-1113
41. Bonkovsky H.L., Mehta S. Hepatitis C: a review and update. J Am Acad Dermatol. 44(2):2001;159-182
42. Callen J.P., af Ekenstam E. Cutaneous leukocytoclastic vasculitis: clinical experience in 44 patients. South Med J. 80(7):1987;848-851
43. Sullivan T.P., King L.E. Jr., Boyd A.S. Colchicine in dermatology. J Am Acad Dermatol. 39(6):1998;993-999
44. Epstein J.H. Phototoxicity and photoallergy. Semin Cutan Med Surg. 18(4):1999;274-284
45. Lee A.Y., Joo H.J., Chey W.Y., Kim Y.G. Photopatch testing in seven cases of photosensitive drug eruptions. Ann Pharmacother. 35(12):2001;1584-1587
46. Moloney F.J., Collins S., Murphy G.M. Sunscreens: safety, efficacy and appropriate use. Am J Clin Dermatol. 3(3):2002;185-191
47. Auquier-Dunant A., Mockenhaupt M., Naldi L., Correia O., Schroder W., Roujeau J.C. Correlations between clinical patterns and causes of erythema multiforme major, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol. 138(8):2002;1019-1024
48. Kokuba H., Imafuku S., Burnett J.W., Aurelian L. Longitudinal study of a patient with herpes-simplex-virus-associated erythema multiforme: viral gene expression and T cell repertoire usage. Dermatology. 198(3):1999;233-242
49. Knowles S.R., Uetrecht J., Shear N.H. Idiosyncratic drug reactions: the reactive metabolite syndromes. Lancet. 356(9241):2000;1587-1591
50. Bastuji-Garin S., Fouchard N., Bertocchi M., Roujeau J.C., Revuz J., Wolkenstein P. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol. 115(2):2000;149-153
51. Viard I., Wehrli P., Bullani R., et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science. 282(5388):1998;490-493
52. Halebian P.H., Shires G.T. Burn unit treatment of acute, severe exfoliating disorders. Annu Rev Med. 40:1989;137-147
53. Bachot N., Revuz J., Roujeau J.C. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol. 139(1):2003;33-36
54. Trent J.T., Kirsner R.S., Romanelli P., Kerdel F.A. Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: The University of Miami Experience. Arch Dermatol. 139(1):2003;39-43
55. Prins C., Kerdel F.A., Padilla R.S., et al. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol. 139(1):2003;26-32
56. Schulz J.T., Sheridan R.L., Ryan C.M., MacKool B., Tompkins R.G. A 10-year experience with toxic epidermal necrolysis. J Burn Care Rehabil. 21(3):2000;199-204
57. Palmieri T.L., Greenhalgh D.G., Saffle J.R., et al. A multicenter review of toxic epidermal necrolysis treated in US burn centers at the end of the twentieth century. J Burn Care Rehabil. 23(2):2002;87-96
58. Gupta A., Eggo M.C., Uetrecht J.P., et al. Drug-induced hypothyroidism: the thyroid as a target organ in hypersensitivity reactions to anticonvulsants and sulfonamides. Clin Pharmacol Ther. 51(1):1992;56-67
59. Ruocco V., Sacerdoti G. Pemphigus and bullous pemphigoid due to drugs. Int J Dermatol. 30(5):1991;307-312
60. Brenner S., Bialy-Golan A., Anhalt G.J. Recognition of pemphigus antigens in drug-induced pemphigus vulgaris and pemphigus foliaceus. J Am Acad Dermatol. 36(6 Pt 1):1997;919-923
61. de Angelis E., Lombardi M.L., Grassi M., Ruocco V. Enalapril: a powerful in vitro non-thiol acantholytic agent. Int J Dermatol. 31(10):1992;722-724
62. Kuechle M.K., Hutton K.P., Muller S.A. Angiotensin-converting enzyme inhibitor-induced pemphigus: three case reports and literature review. Mayo Clin Proc. 69(12):1994;1166-1171
63. Smith E.P., Taylor T.B., Meyer L.J., Zone J.J. Antigen identification in drug-induced bullous pemphigoid. J Am Acad Dermatol. 29(5 Pt 2):1993;879-882
64. Wakelin S.H., Allen J., Zhou S., Wojnarowska F. Drug-induced linear IgA disease with antibodies to collagen VII. Br J Dermatol. 138(2):1998;310-314
65. Paul C., Wolkenstein P., Prost C., et al. Drug-induced linear IgA disease: target antigens are heterogeneous. Br J Dermatol. 136(3):1997;406-411
66. Halevy S., Shai A. Lichenoid drug eruptions. J Am Acad Dermatol. 29(2 Pt 1):1993;249-255
67. Requena L., Requena C. Erythema nodosum. Dermatol Online J. 8(1):2002;1-35
68. Chan H.H., Wing Y., Su R., Van Krevel C., Lee S. A control study of the cutaneous side effects of chronic lithium therapy. J Affect Disord. 57(1-3):2000;107-113
69. Latini A., Carducci M. Psoriasis during therapy with olanzapine. Eur J Dermatol. 13(4):2003;404-405
70. Yung R., Chang S., Hemati N., Johnson K., Richardson B. Mechanisms of drug-induced lupus. IV. Comparison of procainamide and hydralazine with analogs in vitro and in vivo. Arthritis Rheum. 40(8):1997;1436-1443